Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 100

    1.

    Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

    Sharrow AC, Ronnett BM, Thoburn CJ, Barber JP, Giuntoli RL 2nd, Armstrong DK, Jones RJ, Hess AD.

    J Ovarian Res. 2010 Mar 31;3:9.

    PMID:
    20356397
    [PubMed]
    Free PMC Article
    2.

    Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat.

    Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, Hiserodt JC.

    Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):593-9.

    PMID:
    8828419
    [PubMed - indexed for MEDLINE]
    3.

    Final Report on Carcinogens Background Document for Formaldehyde.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

    PMID:
    20737003
    [PubMed - as supplied by publisher]
    4.

    Regulation of transforming growth factor alpha gene expression in an ovarian surface epithelial cell line derived from a human carcinoma.

    Jindal SK, Ishii E, Letarte M, Vera S, Teerds KJ, Dorrington JH.

    Biol Reprod. 1995 May;52(5):1027-37.

    PMID:
    7626702
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.

    Davies BR, Worsley SD, Ponder BA.

    Histopathology. 1998 Jan;32(1):69-80.

    PMID:
    9522220
    [PubMed - indexed for MEDLINE]
    6.

    Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

    Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

    Int J Gynecol Cancer. 2009 Jul;19(5):860-6.

    PMID:
    19574774
    [PubMed - indexed for MEDLINE]
    7.
    9.

    Final Report on Carcinogens Background Document for Styrene.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.

    PMID:
    20737009
    [PubMed - as supplied by publisher]
    10.

    Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures.

    Li AJ, Baldwin RL, Karlan BY.

    Am J Obstet Gynecol. 2003 Jul;189(1):22-7.

    PMID:
    12861133
    [PubMed - indexed for MEDLINE]
    11.

    In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.

    Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS.

    Cancer. 1996 May 1;77(9):1862-72.

    PMID:
    8646686
    [PubMed - indexed for MEDLINE]
    12.

    Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo.

    Davies BR, Auersperg N, Worsley SD, Ponder BA.

    Am J Pathol. 1998 Jan;152(1):297-306.

    PMID:
    9422547
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.

    McCluggage WG, Young RH.

    Semin Diagn Pathol. 2005 Feb;22(1):3-32. Review.

    PMID:
    16512597
    [PubMed - indexed for MEDLINE]
    15.

    Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.

    Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr.

    Clin Cancer Res. 2004 May 15;10(10):3291-300.

    PMID:
    15161682
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.

    Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.

    Clin Cancer Res. 2008 Mar 15;14(6):1726-33.

    PMID:
    18347173
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.

    Zhai Y, Iura A, Yeasmin S, Wiese AB, Wu R, Feng Y, Fearon ER, Cho KR.

    Oncogene. 2011 Oct 6;30(40):4152-62. doi: 10.1038/onc.2011.123. Epub 2011 Apr 18.

    PMID:
    21499300
    [PubMed - indexed for MEDLINE]
    18.

    Overview of resistance to systemic therapy in patients with breast cancer.

    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

    Adv Exp Med Biol. 2007;608:1-22. Review.

    PMID:
    17993229
    [PubMed - indexed for MEDLINE]
    19.

    Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.

    Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, Evangelou A, Rosen B, Murphy KJ, Brown TJ.

    Oncogene. 2007 Jan 11;26(2):198-214. Epub 2006 Jul 10.

    PMID:
    16832351
    [PubMed - indexed for MEDLINE]
    20.

    Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

    Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM.

    Mol Carcinog. 2000 Aug;28(4):236-46.

    PMID:
    10972993
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk